Novo shares sink as weight-loss drug giant unveils 2030 strategy

• Novo Nordisk's 2030 ambition is to scale capacity to serve 10x more people on oral GLP-1.
• The CEO reported 7 million Wegovy pill prescriptions in the U.S. so far.
• The company plans to diversify into new segments like blood and endocrine disorders, and liver disease.
• Novo Nordisk aims for 5 multi-blockbusters by 2030 and 150 billion Danish Krone in pipeline sales by 2035, while also strengthening its diabetes care business.

Novo Nordisk shares are down over 6% despite the company unveiling an ambitious 2030 strategy to scale oral GLP-1 capacity tenfold and diversify into new segments. The CEO highlighted 7 million Wegovy pill prescriptions in the U.S. so far, alongside plans for five multi-blockbusters and strengthening their diabetes care business.